Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Next Previous
X
Search
Trial Profile

A Phase 3, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal Pegcetacoplan Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcetacoplan (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms DERBY
  • Sponsors Apellis Pharmaceuticals

    • Most Recent Events

    • 01 Aug 2024 According to an Apellis Pharmaceuticals media release, final decision from the European regulatory authorities for SYFOVRE in GA in the fourth quarter.
    • 09 Jul 2024 According to an Apellis Pharmaceuticals media release, data from this will be presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting to be held July 17 - 20 in Stockholm, Sweden.
    • 28 Jun 2024 According to an Apellis Pharmaceuticals media release, the company is planning to initiate a re-examination of the marketing authorization application of SYFOVRE with the European Medicines Agency (EMA) and expecting a final opinion to be issued by the CHMP in the second quarter of 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top